stockportfolio.pro
Stocks / BBOT vs GYRE
BBOT vs GYRE
BridgeBio Oncology Therapeutics, Inc. and Gyre Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | Gyre Therapeutics, Inc. (GYRE) | |
|---|---|---|
| Market cap | $0.6B | $0.6B |
| Revenue (latest FY) | $0 | $116.59M |
| Net income (latest FY) | $-134.04M | $5.03M |
| Revenue growth (5y CAGR) | — | 41.0% |
| Net margin | — | 4.3% |
| Return on equity | -32.6% | 4.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 3 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BBOT — free Open GYRE — freeFrequently asked questions
Which is bigger, BBOT or GYRE?
Gyre Therapeutics, Inc. is larger by market capitalization — $0.6B versus $0.6B.
Which grows faster, BBOT or GYRE?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.